Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires $106,396.06 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) major shareholder Venrock Healthcare Capital Par purchased 8,971 shares of the business’s stock in a transaction dated Wednesday, February 12th. The shares were acquired at an average cost of $11.86 per share, for a total transaction of $106,396.06. Following the acquisition, the insider now owns 4,044,684 shares of the company’s stock, valued at approximately $47,969,952.24. The trade was a 0.22 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, February 14th, Venrock Healthcare Capital Par acquired 88,794 shares of Oruka Therapeutics stock. The shares were bought at an average cost of $11.44 per share, with a total value of $1,015,803.36.
• On Monday, February 10th, Venrock Healthcare Capital Par purchased 574 shares of Oruka Therapeutics stock. The shares were bought at an average price of $10.90 per share, with a total value of $6,256.60.

Oruka Therapeutics Stock Down 9.2 %

Oruka Therapeutics stock traded down $0.97 during midday trading on Thursday, reaching $9.56. The stock had a trading volume of 414,591 shares, compared to its average volume of 292,147. Oruka Therapeutics, Inc. has a 1-year low of $9.53 and a 1-year high of $53.88. The company’s fifty day moving average is $14.72. The stock has a market capitalization of $334.59 million, a PE ratio of -1.53 and a beta of 0.77.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at approximately $54,000. AlphaCentric Advisors LLC acquired a new position in shares of Oruka Therapeutics in the fourth quarter valued at $119,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Oruka Therapeutics in the fourth quarter valued at $144,000. Squarepoint Ops LLC bought a new position in shares of Oruka Therapeutics in the fourth quarter valued at about $236,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Oruka Therapeutics during the 4th quarter worth about $303,000. Institutional investors own 56.44% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on ORKA. HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a report on Friday, February 7th. Wedbush reaffirmed an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Finally, Wolfe Research initiated coverage on Oruka Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $20.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $39.86.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.